Sight Sciences, Inc. announced the results as published in the American Journal of Ophthalmology ("AJO") International of the large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery ("MIGS") technologies. Using the American Academy of OphthalmologyIRIS®? Registry (Intelligent Research in Sight), the largest specialty society clinical data registry in all of medicine and the first comprehensive eye disease clinical registry in the United States, this large-scale MIGS study evaluated long-term 2-year post-surgical outcomes among patients with primary open-angle glaucoma ("POAG") treated with the three most commonly used FDA-approved/cleared ab interno MIGS devices in the U.S. (OMNI Surgical System ("OMNI"), Hydrus®?

Microstent, and iStent inject®?) combined with cataract surgery, as well as for cataract surgery alone. OMNI facilitates a unique implant-free, ab interno procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway. OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle Glaucoma.

Baseline Patient Characteristics: The entire study cohort consisted of 77,391 patients with glaucoma and 109,745 glaucomatous eyes; 6,632 patients and 9,000 eyes received a MIGS procedure in combination with cataract surgery, and the remaining received cataract surgery alone; The four cohorts had generally similar baseline characteristics in terms of intraocular pressure ("IOP") and mean number of IOP-lowering medications; The overall population was divided into two subgroups depending on the baseline, pre-surgical lOP; 18 mmHg and 18 mmHg.